Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 66%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

Bristol-Myers Squibb , which is set to buy biotechnology company Celgene Corp soon for US$74 billion, posted better-than-expected second-quarter ...

NEW YORK: Bristol-Myers Squibb , which is set to buy biotechnology company Celgene Corp soon for US$74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Excluding one-time items, the drugmaker said it earned US$1.18 a share, beating analyst expectations of US$1.07 a share, according to IBES data from Refinitiv. Sales of Eliquis rose 24per cent to US$2.04 billion and Orencia sales rose 9per cent to US$778 million. Both drugs performed better than analysts expected.

Opdivo combined with chemotherapy failed to extend overall survival more than chemotherapy alone in patients with advanced non-squamous non-small cell lung cancer .

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 6. in PT
 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Portugal Últimas Notícias, Portugal Manchetes